title: Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
abstract: A. Tzanidis, S. Lim, R. D. Hannan, F. See, A. M. Ugoni and H. Krum. Combined Angiotensin and Endothelin Receptor Blockade Attenuates Adverse Cardiac Remodeling Post-Myocardial Infarction in the Rat: Possible Role of Transforming Growth Factor beta(1). Journal of Molecular and Cellular Cardiology (2001) 33, 969-981. Myocardial infarction (MI) is associated with activation of the vasoconstrictor peptides, angiotensin II (AngII) and endothelin-1 (ET-1), which are thought to contribute to adverse cardiac remodeling and dysfunction. The present study sought to determine whether combined AngII and ET receptor blockade improves cardiac remodeling over individual treatments in an experimental model of left ventricular myocardial infarction (LVMI) in the rat. Groups of eight female Sprague-Dawley rats were randomized at 24 h post-LVMI to 1 week treatment with either vehicle, an ET(A/B)receptor antagonist (bosentan), an AT(1)receptor antagonist (valsartan), or combined treatment. Vehicle-treated animals developed LV dysfunction with extensive accumulation of collagen type I and increased alpha(1)(I) procollagen mRNA compared to sham controls. Whilst individual receptor blockade with either bosentan or valsartan reduced LVEDP towards sham control levels, there were no significant changes to myocardial collagen deposition in comparison to vehicle. In contrast, improved ventricular function by combined treatment was associated with reduced type I collagen deposition within left ventricular non-infarct regions, as well as reduced peptide distribution and cardiac gene expression of the profibrogenic peptide, transforming growth factor beta(1)(TGF beta(1)). These data demonstrate that combined AngII and ET receptor blockade has beneficial effects on myocardial fibrogenesis over individual treatments during adverse cardiac remodeling early post-MI.
authors.affiliation: Department of Medicine/Epidemiology and Preventive Medicine, Monash University Medical School, Alfred Hospital, Commercial Road, Prahran 3181, Victoria, Australia. alex.tzanidis@med.monash.edu.au
authors.forename: A
authors.initials: A
authors.lastname: Tzanidis
authors.forename: S
authors.initials: S
authors.lastname: Lim
authors.forename: R D
authors.initials: RD
authors.lastname: Hannan
authors.forename: F
authors.initials: F
authors.lastname: See
authors.forename: A M
authors.initials: AM
authors.lastname: Ugoni
authors.forename: H
authors.initials: H
authors.lastname: Krum
mesh_terms: D057911:Angiotensin Receptor Antagonists; D000818:Animals; D015152:Blotting, Northern; D000077300:Bosentan; D003094:Collagen / Q000096:biosynthesis; D065128:Endothelin Receptor Antagonists; D005260:Female; D005347:Fibroblasts / Q000378:metabolism; D006439:Hemodynamics; D017379:Hypertrophy, Left Ventricular / Q000378:metabolism; D007150:Immunohistochemistry; D008264:Macrophages / Q000378:metabolism; D009000:Monocytes / Q000378:metabolism; D009203:Myocardial Infarction / Q000378:metabolism*; D009206:Myocardium / Q000378:metabolism; D011347:Procollagen / Q000096:biosynthesis; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D013449:Sulfonamides / Q000494:pharmacology; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000502:physiology*; D053773:Transforming Growth Factor beta1; D014633:Valine / Q000031:analogs & derivatives* / Q000494:pharmacology; D000068756:Valsartan; D018487:Ventricular Dysfunction, Left / Q000378:metabolism
chemical_list: D057911:Angiotensin Receptor Antagonists; D065128:Endothelin Receptor Antagonists; D011347:Procollagen; D012333:RNA, Messenger; D013449:Sulfonamides; D013777:Tetrazoles; C508962:Tgfb1 protein, rat; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D000068756:Valsartan; D003094:Collagen; D014633:Valine; D000077300:Bosentan